(Q27132753)

Tenofovir disoproxil (English)

18 November 2016

chemical formula

C₁₉H₃₀N₅O₁₀P

1 reference

Tenofovir disoproxil (English)

18 November 2016

canonical SMILES

CC(C)OC(=O)OCOP(=O)(COC(C)CN1C=NC2=C1N=CN=C2N)OCOC(=O)OC(C)C

1 reference

Tenofovir disoproxil (English)

18 November 2016

isomeric SMILES

C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C

1 reference

Tenofovir disoproxil (English)

Tenofovir Disoproxil Mylan

18 November 2016

active ingredient in

1 reference

European Medicines Agency product number

EMEA/H/C/004049

reference URL

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004049/human_med_002048.jsp

22 March 2017

1 reference

14 February 2018

medical condition treated

hepatitis B

1 reference

Drug Indications Extracted from FAERS

2 October 2018

chronic hepatitis B

1 reference

Drug Indications Extracted from FAERS

2 October 2018

HIV/AIDS

1 reference

Drug Indications Extracted from FAERS

human immunodeficiency virus infectious disease

2 October 2018

start time

17 January 2012

approved by

Food and Drug Administration

1 reference

Inxight: Drugs Database

https://drugs.ncats.io/drug/F4YU4LON7I

2 November 2018

reference URL

https://aidsinfo.nih.gov/drugs/290/tenofovir-disoproxil-fumarate/0/patient

hepatitis B

start time

17 January 2012

approved by

Food and Drug Administration

1 reference

Inxight: Drugs Database

https://drugs.ncats.io/drug/F4YU4LON7I

2 November 2018

reference URL

https://aidsinfo.nih.gov/drugs/290/tenofovir-disoproxil-fumarate/0/patient

significant drug interaction

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aceclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

atazanavir

kidney failure

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aceclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

lactic acidosis

1 reference

A reference set of clinically relevant adverse drug-drug interactions

peripheral neuropathy

1 reference

A reference set of clinically relevant adverse drug-drug interactions

diarrhea

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pancreatitis

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Commons category

Tenofovir disoproxil

0 references

catalog

CAS COVID-19 Anti-Viral Candidate Compounds

0 references

Identifiers

InChI

InChI=1S/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)/t14-/m1/s1

1 reference

Tenofovir disoproxil (English)

18 November 2016

2 references

Tenofovir disoproxil (English)

18 November 2016

ChEBI release 2020-09-01

CAS Registry Number

201341-05-1

2 references

Global Substance Registration System

UNII

F4YU4LON7I

tenofovir disoproxil (English)

18 November 2016

https://commonchemistry.cas.org/detail?cas_rn=201341-05-1

9 April 2021

1 reference

Tenofovir disoproxil (English)

18 November 2016

2 references

Tenofovir disoproxil (English)

18 November 2016

Reaxys registry number

9018187

1 reference

tenofovir disoproxil (English)

7 October 2016

ChEBI ID

63717

mapping relation type

2 references

TENOFOVIR DISOPROXIL (English)

18 November 2016

International Chemical Identifier

InChI

InChI=1S/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)/t14-/m1/s1

1 reference

TENOFOVIR DISOPROXIL (English)

18 November 2016

2 references

inferred from InChIKey

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

1 reference

2 references

DSSTOX compound identifier

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.114.051

27 December 2018

ECHA Substance Infocard ID

2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-, 1,9-bis(1-methylethyl) ester, 5-oxide (English)

quotation

CAS no.: 201341-05-1 (English)

100.114.051

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.114.051

27 December 2018

2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-, 1,9-bis(1-methylethyl) ester, 5-oxide (English)

quotation

CAS no.: 201341-05-1 (English)

RxNorm ID

300195

1 reference

Global Substance Registration System

UNII

F4YU4LON7I